Abeona Therapeutics to Present EB-101 Data at Society for Investigative Dermatology Annual Meeting

Long-term follow up data from a completed Phase 1/2 study evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the 77th Annual Meeting of the Society for Investigative Dermatology (SID) in Chicago. The data will be presented by Stanford University researcher Shaundra Eichstadt, MD in two forums at the meeting, according to Abeona Therapeutics, Inc.

As previously reported, these data show that three years after treatment with EB-101, a majority of RDEB patients had durable wound healing. Notable improvements were also reported in outcomes associated with wound healing, including patient reported reductions in pain and itching. No serious treatment-related adverse events were observed at three years, and no replication competent virus was present at any time point.